Ottobock SE & Co. KGaA, the global leader in human bionics, has reported sustained growth for the third quarter and the first nine months of 2026, even as the company navigates an increasingly complex international healthcare landscape. The Duderstadt-based firm announced an organic core revenue growth of 6.4 percent for Q3, bringing its nine-month growth to 6.6 percent, a performance consistent with its objectives for the year.
The company’s financial results highlight a clear divergence in global market performance. The EMEA region led the way with 8.0 percent organic core growth in the third quarter, bolstered by significant double-digit growth in the B2B sector. Meanwhile, the Asia-Pacific (APAC) market saw a strong recovery, surging 17.9 percent in Q3 following a slower second quarter. In contrast, the Americas region continued to face headwinds, reporting a 1.8 percent decline in core revenue, a trend attributed to challenging prior-year comparisons and regional market softness in Brazil and Canada.
Underlying core EBITDA margins demonstrated resilience, climbing to 27.7 percent in Q3—an increase of 110 basis points compared to the same period last year. This margin improvement was primarily driven by the company’s “Products & Components” (B2B) division, which remains the primary engine of Ottobock’s growth. High-tech innovations, including the C-Brace Interim and myoelectric Michelangelo hand, have proven essential in maintaining this momentum.
However, the “Patient Care” (B2C) segment, which encompasses the company’s network of over 430 clinics worldwide, experienced slower growth at 1.7 percent for the quarter. Ottobock’s CEO, Oliver Jakobi, noted that while the company continues to outperform the broader market, the operating environment is becoming more demanding. “We are seeing a more challenging market environment, particularly as reimbursement frameworks evolve in several key markets,” Jakobi explained. In many European regions, the administrative process for securing reimbursement approvals has lengthened, creating a bottleneck that delays the translation of patient demand into realized revenue.
Despite these hurdles, Ottobock has reaffirmed its 2026 financial guidance. The company expects organic core revenue growth for the full year to land between 6.0 and 8.0 percent, with an underlying core EBITDA margin maintained above 27.0 percent. Management remains confident that the structural drivers of demand—an aging global population and the ongoing evolution of bionic technology—will continue to underpin long-term growth.
Financial health remains a key focus for the group. Underlying net income for the nine-month period reached EUR 138.0 million, representing a 16.3 percent increase over the previous year. While free cash flow of EUR 151.1 million was slightly lower than the prior year’s figure, largely due to increased tax obligations, the company’s leverage ratio improved to 2.3x by the end of September. This stability has been maintained even after the strategic acquisition of the Blatchford patient care business in Norway earlier in 2026.
As the company looks toward the final quarter of the year, it anticipates a moderate seasonal uplift. While the “complex reimbursement landscape” is expected to persist, leadership is banking on the strength of its innovation pipeline and internal operational efficiencies to sustain its market position. The company is expected to provide further details regarding its 2027 outlook when it releases its full-year 2026 results in March 2027.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
